The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Tags : Bridge Biotherapeutics
Shots: Atomwise to receive ~ $1.08B as an up front, milestones and royalties on the success of the programs and will utilize its AI technology to evaluate Pellino E3 ubiquitin […]readmore
Shots: Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process […]readmore
Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration […]readmore